

[Arsenic trioxide](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.1. Cytotoxic medicines](#)

ATC codes: [L01XX27](#)

EMLc

Indication

Acute myeloid leukaemia with recurrent genetic abnormalities ICD11 code: [2A60.0](#)

Medicine type

Chemical agent

List type

Complementary

Formulations

Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion ; 2 mg per mL concentrate for solution for infusion

EML status history

First added in 2019 ([TRS 1021](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Arsenic trioxide](#)

DrugBank

[Arsenic trioxide](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of additional strength dosage form of arsenic trioxide (concentrate for solution for infusion 2 mg/mL) to the EML and EMLc.